Article
03 Oct 2025
Life Sciences And Medtech Policy Update: Key Things To Know Q4 2025
AUTHORS CONTENT
Article
07 Aug 2025
Move Fast: FDA Is Accepting Submissions For The Pilot Program Class For FDA Commissioner's National Priority Voucher Program
Article
05 Aug 2025
340B Rebate Pilot Program Proposed By HRSA
Article
25 Jul 2025
DOJ-HHS Announces False Claims Act Working Group, Emphasizes Healthcare Fraud Enforcement Priorities
Article
08 Jul 2025
Changes To Birthright Citizenship And The Impact On Fertility And Assisted Reproduction Clinics
Article
04 Jun 2025
State Drug Transparency Laws — 2025 Update
Article
04 Jun 2025
Prescription Drug Affordability Review Boards — 2025 Update
Article
14 May 2025
Most Favored Nation Drug Pricing Executive Order Resurrects Prior President Trump Policy
Article
03 Oct 2024
A Look Ahead In Life Sciences: What We Are Tracking In The Fourth Quarter Of 2024 And Beyond
Article
09 Jan 2024
A Look Ahead In Life Sciences: What We Are Tracking In Q1 2024 And Beyond
Article
29 Nov 2023
A Practical Look At OIG's New Compliance Guidance
Article
22 Nov 2023
Significant 340B Drug Pricing Program Litigation May Impact 340B Scope
Article
10 Nov 2023
2023 State Drug Transparency Law Development Update
Article
03 Nov 2023
White House Unveils Landmark Executive Order On Safe, Secure, And Trustworthy Artificial Intelligence
Article
10 Oct 2023
Federal Court Strikes Down Copay Accumulator Programs
Article
11 Apr 2023
CMS Issues Guidance And Solicits Comment On The 2026 Inflation Reduction Act Part D Negotiation Process
Article
22 Mar 2023
HHS To Create New Potential Medicare Pricing Models For Cell And Gene Therapy, Drugs Subject To Accelerated FDA Approval, And "High-Value" Generics
Article
28 Feb 2023
CMS Issues Proposed Guidance On Inflation Rebates Under Medicare Part B
Article
28 Feb 2023
CMS Issues Proposed Guidance On Inflation Rebates Under Medicare Part D
Article
16 Feb 2023
340B Drug Pricing Program Reform Considerations
